Anokion SA is a Swiss biotechnology company that aims to make a meaningful difference in the lives of patients suffering from autoimmune diseases by restoring normal immune tolerance. The company is focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes. Anokion’s distinct approach leverages the company’s immune-based platform, which targets natural pathways in the liver to restore immune tolerance and address the underlying cause of autoimmune disease.
Location: United States, Massachusetts, Cambridge
Employees: 11-50
Total raised: $112.59M
Founded date: 2010
Investors 1
| Date | Name | Website |
| - | VentureLab | venturelab... |
Funding Rounds 3
| Date | Series | Amount | Investors |
| 07.11.2022 | - | $35M | - |
| 13.09.2019 | - | $40M | - |
| 09.05.2014 | Series A | $37.59M | - |
Mentions in press and media 22
| Date | Title | Description |
| 07.10.2024 | FDA approvals and clinical advancements propel life sciences startups forward | Alentis Therapeutics, a clinical-stage biotech company focused on developing treatments for cancer and fibrosis, has received FDA clearance for an Investigational New Drug (IND) application for ALE.P02, a novel anti-CLDN1 ADC targeting squ... |
| 10.05.2023 | Biotech startups turn gear into Phase 2 clinical trials | |
| 21.10.2022 | Pfizer invests $35 million in Anokion | |
| 18.10.2022 | Anokion Raises $35M in Equity Funding from Pfizer | Anokion, a Lausanne, Switzerland-based clinical-stage biotechnology company, raised $35M in Equity funding. The round was led by Pfizer Breakthrough Growth Initiative. In conjunction with the funding, Michael Vincent, M.D., Ph.D., senior vi... |
| 24.03.2021 | Anokion advances second drug candidate into clinical trials | Anokion is a Swiss biotech company focused on both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis and type 1 diabetes. Anokin's distinct approach leverages the company’s immune-based platform, which tar... |
| 24.03.2021 | Anokion advances second drug candidate into clinical trials | |
| 26.02.2021 | Female leaders at the top | |
| 26.02.2021 | Female leaders at the top | EBAMed SA, developer of medical technologies to transform the treatment of cardiac arrhythmias, has appointed experienced specialist Marina Izzo as CEO. Izzo served as CEO for Cardionovum, an innovative developer of drug-coated balloon tech... |
| 27.01.2020 | A flourishing year for the EPFL and its spin-offs | |
| 27.01.2020 | A flourishing year for the EPFL and its spin-offs | The École Polytechnique Fédérale de Lausanne (EPFL) is one of the leading research institutes in Switzerland dedicated to promoting knowledge and technology transfer enabling students to transform their research projects into real businesse... |
Show more